|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Sezary Syndrome
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our aim was to evaluate the respective value of CD26, CD7 and KIR3DL2 expression on CD4<sup>+</sup> T cells and total lymphocytes at initial diagnosis of SS.
|
31487384 |
2019 |
|
Sezary Syndrome
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm the activity in patients with Sézary syndrome and explore the role of IPH4102 in other subtypes of T-cell lymphomas that express KIR3DL2.
|
31253572 |
2019 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
Differential expression of PD-1 and KIR3DL2 may represent a tool for distinguishing MF and SS, as well as a means of monitoring treatment response.
|
31585624 |
2019 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
Moreover, KIR3DL2 immunostaining allowed the assessment of treatment efficiency and specificity toward tumor cells, the detection of the residual disease following treatment, and the occurrence of relapse, even though patients clinically experienced complete remission and/or undetectable circulating Sézary cells by cytomorphologic analysis.<b>Conclusions:</b> We show that KIR3DL2 expression is the most sensitive diagnostic criterion of Sézary syndrome when compared with all other available biological criteria.
|
28119365 |
2017 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
These characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sézary syndrome, CD30<sup>+</sup> cutaneous lymphoma, and transformed mycosis fungoides.
|
28912774 |
2017 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
In light of these findings, CD158k/KIR3DL2 transcripts appear to be a unique molecular marker of SS in skin samples, allowing differential diagnosis with benign EID in routine practice.
|
17703174 |
2008 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
LHGDN |
CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
|
18061949 |
2008 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
LHGDN |
[KIR3DL2: a new step for the management of patients with Sezary syndrome].
|
16962036 |
2006 |
|
Sezary Syndrome
|
0.090 |
Biomarker
|
disease |
BEFREE |
Identification of the malignant cells in Sézary syndrome cannot be achieved by T-cell clonality studies or by TCR Vbeta monoclonal antibody (mAb) analysis alone; it also relies on CD158k phenotyping.
|
16418328 |
2006 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
These characteristics have implicated KIR3DL2 in several pathologies: ankylosing spondylitis and cutaneous T-cell lymphomas such as Sézary syndrome, CD30<sup>+</sup> cutaneous lymphoma, and transformed mycosis fungoides.
|
28912774 |
2017 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
KIR-3DL2+CD4+ T cells in patients with ankylosing spondylitis were oligoclonal and enriched for markers of T cell activation and for the gut homing receptor CCR9.
|
26841353 |
2016 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Analysis of Killer Cell Immunoglobulin-like Receptor Genes and Their HLA Ligands in Iranian Patients with Ankylosing Spondylitis.
|
26996109 |
2016 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
ERAP1 activity determines surface expression of HLA-B27 FHCs and potentially promotes Th17 responses in AS through binding of HLA-B27 FHCs to KIR3DL2.
|
26130142 |
2016 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Increased expression of HC10-reactive molecules on AS monocytes was seen, supporting the possible role of the KIR3DL2/B272 pair in the pathogenesis of AS.
|
25381967 |
2014 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
KIR3DL2 binds to HLA-B27 dimers and free H chains more strongly than other HLA class I and promotes the expansion of T cells in ankylosing spondylitis.
|
23440420 |
2013 |
|
Ankylosing spondylitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Diversity of killer cell immunoglobulin-like receptor genes in uveitis associated with autoimmune diseases: ankylosing spondylitis and Behçet disease.
|
23697859 |
2013 |
|
Ankylosing spondylitis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Neither the KIR gene content of particular KIR haplotypes nor KIR3DL2 polymorphisms contribute to AS.
|
19019897 |
2009 |
|
Lupus Erythematosus, Systemic
|
0.070 |
Biomarker
|
disease |
BEFREE |
In vitro, P140 acts directly on a particular form of autophagy called chaperone-mediated autophagy, which seems to be hyperactivated in certain subsets of lymphocytes in lupus and in other autoinflammatory settings.
|
30219390 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.070 |
Biomarker
|
disease |
BEFREE |
This mechanism appears to switch off the downstream events leading to secretion of pathogenic autoantibodies, thus explaining the highly promising results obtained in clinical trials of P140 (Lupuzor) for the treatment of lupus.
|
29499102 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Association between killer cell immunoglobulin-like receptor (KIR) polymorphisms and systemic lupus erythematosus (SLE) in populations: A PRISMA-compliant meta-analysis.
|
28272205 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We will aim to analyse the role of killer cell immunoglobulin-like receptor (KIR) genotypes and their existence with the respective HLA ligands in patients with SLE and SSc.
|
26960450 |
2016 |
|
Lupus Erythematosus, Systemic
|
0.070 |
Biomarker
|
disease |
BEFREE |
Association of killer cell immunoglobulin-like receptor and human leucocyte antigen-Cw gene combinations with systemic lupus erythematosus.
|
25581336 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.070 |
Biomarker
|
disease |
BEFREE |
Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus.
|
19926642 |
2010 |
|
Lupus Erythematosus, Systemic
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus.
|
18755860 |
2008 |